ASIT biotech initiates the search for a strategic commercial partner for the future marketing of gp-
• The Sage Group, an internationally recognized consulting group, has been appointed to identify a commercial partner with a special focus on the US market • ASIT biotech has developed an innovative immunotherapy product entering a confirmatory phase III study in grass pollen induced allergic rhinitis, requiring only a 3-week treatment course prior to the pollen season • ASIT biotech is meeting potential partners at the Bio-Europe 2018 partnering conference in Copenhagen this week Brussels, Belgium, 5 November 2018 - 08:00 am CET - ASIT biotech (ASIT - BE0974289218), a Belgian clinical-stage biopharmaceutical company focused on the research and development of breakthrough allergy immunothera